Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angong Jiangyawan for hypertension inadequately controlled on background antihypertensive therapy
ChiCTR-IPR-17012500Phase 4Recruiting
- Sponsor
- Beijing Hospital of Traditional Chinese Medicine
- Start
- Jul 2017
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of Angong Jiangyawan in hypertension (HTN) (2 arms), sponsored by Beijing Hospital of Traditional Chinese Medicine. Primary endpoint: Change from baseline in mean sitting diastolic blood pressure. Started Jul 2017; status: recruiting.
02
Drugs
Angong Jiangyawan
03
Conditions
hypertension (HTN)
Beyond the preview
Go deeper on ChiCTR-IPR-17012500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17012500.